Full-Time

Global Supply Chain Product Leader

Director

Confirmed live in the last 24 hours

Sanofi

Sanofi

10,001+ employees

Global healthcare company providing pharmaceuticals and vaccines

Biotechnology
Healthcare

Senior, Expert

Cambridge, MA, USA

Category
Supply Chain Management
Operations & Logistics
Required Skills
Inventory Management
Data Analysis

You match the following Sanofi's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Bachelor’s degree in Business Administration, Engineering, Supply Chain or equivalent.
  • 8+ years in manufacturing or supply in biopharmaceutical industry or equivalent.
  • 2+ years of leadership experience in highly complex global work environment (indirect management, ability to influence, and complex stakeholder’s management).
  • 5+ years of experience of conducting data-driven analysis and communication findings to management.
  • 4+ years of experience with managing financials and budgeting (including inventory management).
  • 4+ years of experience of product launches or transitions
  • 4+ years of experience of lifecycle management in the pharmaceutical industry, or equivalent.
  • Fluent in English.
Responsibilities
  • Accountable for E2E Supply Chain strategy for a product or set of products.
  • Defines in accordance with segmentation category the Supply Chain strategy for a product or set of products (safety stock, manage LCM timelines with Regulatory, target split between sourcing nodes, distribution network).
  • Supports Products Resilience and Contingency Planning in accordance with products segmentation.
  • Defines E2E product policies including inventory and safety stock policy across the network.
  • Accountable for E2E Supply Chain inventory levels for a product or set of products.
  • In conjunction with Process and Business Excellence, drives continuous improvement on inventory policies and deployment processes.
  • Drives inventory optimization for their portfolio and ensures product roadmap has inventory optimization strategies (including End to end Lead Time) to drive improvements year over year on inventory.
  • Translates the inventory optimization Plan into the Financial inventory exercises (Budget, T1, T2, Strat plan) and contribute to improve the financial inventory process through effective usage of Kinaxis.
  • Accountable for Products or set of products Demand & Supply balancing on IBP & S&OE horizon.
  • Represents product supply in the global IBP process & committees (GDR, TA demand review, GSR, MBR).
  • Is accountable for correct validated & propagated net demand in Kinaxis across all nodes for his/her products (DS, DP, FG).
  • Understands demand patterns and performance on a global level and deep dives when forecast deviation or larger changes occur (SKU, Indications, Demand Divers, Market performance).
  • Accountable for supply continuity in the frame of products Life Cycle Management along the IBP horizon.
  • Focal Point for supply matters to GBU and Franchise for both internal products and external partnerships on S&OE and IBP horizon.
  • Leads recovery planning in case of OOS risk for maximum containment.
  • Leads global crisis & allocation process coordinated with Franchises (SPC & Gen Med only; VGDM role in Vaccines) on IBP & S&OE horizon.
  • Prioritization in case of constraints for respective products based on supply scenarios provided by Product Planners and Global Supply Planning Team.
  • Promotes & supports usage of technical solutions to automate scenario planning and optimize product supply planning (Kinaxis, dVSM, Plai).
  • Drives and supports new product launches & other life-cycle management programs.
  • Drives E2E Supply Chain readiness for new product launches (master data, safety stock policy) aligned with IPL Team, Global regulatory, distribution network).
  • Contributes to the convergence life cycle management process and developing supply assessments according to the regulatory changes across the IBP horizon.
  • Manages the product through its lifecycle (from launch through decommission including SKU optimization).
  • Ensure the product roadmap in the IBP is aligned with the Strategic Product Supply Chain Plan and is communicated with Supply Planning/sites and platforms (e.g., production of product in a new plant).
  • Safeguards strategic decisions are reflected in Kinaxis (e.g., product can be produced starting 202x in site XYZ).
Desired Qualifications
  • Advanced understanding and experience with the Integrated Business Planning process.
  • 8+ years of demand forecast or supply management experience.
  • Knowledge of pharmaceutical manufacturing quality systems and regulatory submissions process.
  • Knowledge of systems and tools such as Kinaxis, dVSM and PLAI.
  • 8+ years of successful experience and demonstrated ability working in matrix environments (cross Functional and multi global location stakeholders’ management).
  • Apply TRT (Thoughtful Risking Taking) methodology to manage business risks and build contingency plans.
  • Strategic thinking with a comprehensive approach to connect the end-to-end supply chain.
  • Capacity to work transversally.
  • APICS certification.

Sanofi provides healthcare solutions through its pharmaceutical and biotechnology products, focusing on treatments and vaccines for various medical conditions. The company conducts extensive research and development to create new therapies and improve existing ones, particularly in areas like immunology, oncology, and rare diseases. Sanofi's products include prescription medicines, over-the-counter items, and vaccines, which are distributed to patients, healthcare professionals, and governments. What sets Sanofi apart from its competitors is its strong emphasis on scientific innovation and strategic partnerships, allowing it to maintain a diverse product pipeline and a global presence. The company's goal is to enhance health outcomes and improve the quality of life for individuals worldwide.

Company Size

10,001+

Company Stage

IPO

Total Funding

$2B

Headquarters

Paris, France

Founded

1973

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi's Sarclisa approval expands its oncology portfolio in the EU.
  • The partnership with BrightInsight accelerates drug development and improves patient outcomes.
  • The €2 billion share buyback reflects financial confidence and shareholder value commitment.

What critics are saying

  • Increased competition in multiple myeloma treatments may impact Sanofi's market share.
  • Regulatory scrutiny on new drugs like tolebrutinib could delay approvals.
  • The €5 billion share buyback may limit funds for R&D or acquisitions.

What makes Sanofi unique

  • Sanofi's R&D focuses on unmet needs in immunology, oncology, and rare diseases.
  • The company leverages strategic partnerships to enhance digital health solutions and patient outcomes.
  • Sanofi's global reach allows it to navigate diverse regulatory environments effectively.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Webrazzi
Feb 17th, 2025
Sanofi Pharmup Girişimcilik Programı’Nın 6. Dönemi Için Başvurular Başladı! [Sponsorlu İçerik]

Sanofi’nin sağlık sektöründe katma değer yaratacak yenilikçi fikirlerin gelişimine destek olmak için Endeavor ile birlikte hayata geçirdiği Girişimcilik Programı PharmUp’ın 6. dönem başvuruları başladı.Türkiye’nin girişimcilik alanındaki köklü kurumlarından Endeavor iş birliğinde gerçekleşecek 6. dönem takvimine göre, başvurular 25 Şubat 2025 tarihine kadar sanofi.com.tr/tr/pharmup üzerinden yapılabilecek. Yeni dönemin kategorileri Akıllı Sağlık Cihazları ve Diagnostik Çözümler (giyilebilir teknolojiler ve hızlı test araçları), Medikal Eğitim ve İletişim Araçları, Sağlıklı Yaşam Çözümleri, Dijital Sağlık ve Teletıp, Veri Yönetimi ve Analitiği, Kurumsal Dijital Dönüşüm olarak belirlendi.Sağlık sektöründe hastaların hayatını iyileştirme adına dijital çözümler üreten fikirlerin hayat bulduğu program PharmUp’ta seçilecek girişimler, mentorluk desteği ve eğitimler içeren 3 aylık hızlandırma dönemine başlayacak. Bu süreçte ürünlerini olgunlaştıran start-up’lar, sonrasında gerçekleştirilecek Demo Day ile sektörün önde gelen isimlerine projelerini tanıtma şansı bulacak ve Sanofi ile iş birliği fırsatı sunulacak. Bunlara ek olarak, programa katılacak girişimciler arasından belirlenecek kişiler, Paris’te gerçekleşen Viva Technology Fuarı’na Sanofi sponsorluğunda katılma imkânı bulacak.PharmUp’ta 2019’dan beri 27 girişimciye destek verildiİlki 2019 yılında gerçekleşen programa, bugüne kadar toplamda 300’e yakın girişimci başvuru yaptı

PharmiWeb
Feb 7th, 2025
Execution Of A Share Buyback Agreement For Up To €2 Billion

Paris, February 7, 2025. On January 30, 2025, Sanofi announced its intention to execute a share buyback program in 2025 of €5 billion, preferably through block trades and in the open market with the purpose of cancellation.A first tranche of this program was announced on February 3, 2025, and executed on February 5, 2025, for an amount of €3 billion, through an off-market block trade with the long-standing shareholder L’Oréal.On February 6, 2025, Sanofi has entered into a mandate with an investment service provider for the second tranche of this program. Under the terms of this mandate, Sanofi will repurchase its own shares for a total consideration of up to €2 billion, between February 7, 2025 and December 31, 2025 at the latest1.About SanofiWe are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNYMedia RelationsSandrine Guendoul | + 33 6 25 09 14 25 | [email protected] Berland | + 1 215 432 0234 | [email protected]éo Le Bourhis | + 33 6 75 06 43 81 | [email protected] Obrist | + 33 6 77 21 27 55 | [email protected] Rouault | + 33 6 70 93 71 40 | [email protected] Gilbert | + 1 516 521 2929 | [email protected] RelationsThomas Kudsk Larsen |+ 44 7545 513 693 | [email protected]é Kaisserian | + 33 6 47 04 12 11 | [email protected] Lauscher | + 1 908 612 7239 | [email protected] Browne | + 1 781 249 1766 | [email protected] Pham | + 33 7 85 93 30 17 | [email protected] Elgoutni | + 1 617 710 3587 | [email protected] Châtelet | + 33 6 80 80 89 90 | [email protected] forward-looking statementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended

PharmiWeb
Jan 22nd, 2025
Sarclisa Approved In The Eu As The First Anti-Cd38 Therapy In Combination With Standard-Of-Care Vrd To Treat Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Approval is based on positive results from the IMROZ phase 3 study, demonstrating Sarclisa in combination with standard-of-care treatment significantly improved PFS, compared to the standard of care alone in TI NDMMRepresents third indication in the EU, including two for the treatment of adult patients with R/R MM, and one in NDMMParis, January 22, 2025. Following the adoption of a positive opinion by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), the EU has approved Sarclisa in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult patients with newly diagnosed multiple myeloma (NDMM) ineligible for autologous stem cell transplant (ASCT), based on data from the IMROZ phase 3 study. With the expanded marketing authorization, Sarclisa is the first anti-CD38 therapy in combination with VRd in this patient population in the EU.Olivier NatafGlobal Head of Oncology at Sanofi“While there have been many important advancements in multiple myeloma treatment over the past decade, there remains a significant unmet need in the front-line setting, particularly for transplant-ineligible patients. With today’s decision the 27 countries in the EU will have access to a potentially transformative new combination regimen, marking a significant step forward in our mission to make a meaningful difference in multiple myeloma treatment.”In September 2024, the US Food and Drug Administration (FDA) approved Sarclisa in combination with VRd for the treatment of adult patients with NDMM who are not eligible for ASCT, representing the first global approval for Sarclisa in the front-line setting. In addition, the FDA granted orphan drug exclusivity for Sarclisa in the approved indication. Beyond the US and the EU, regulatory submissions for Sarclisa in NDMM not eligible for ASCT are under review in Japan and in China.About SarclisaSarclisa (isatuximab) is a CD38 monoclonal antibody that binds to a specific epitope on the CD38 receptor on MM cells, inducing distinct antitumor activity

Webrazzi
Dec 24th, 2024
Sanofi’Nin Girişimcilik Programı Care4Rare'In Demo Day'Inde Sunum Yapan Girişimler

Sürdürülebilir sağlık için ortak hareket etme vizyonuyla çalışmalar yürüten TÜSAP Platformu, sağlık sektörünün mevcut durumundan yola çıkarak vizyon tartışmaları yapmak ve sektörün geleceğini etkileyecek nitelikli bilgiler üretmek amacıyla 40. Vizyon Toplantısı’nı, Sanofi’nin katkılarıyla düzenledi.Zirvede Sanofi’nin PharmUp Girişimci Destek Programı kapsamında hayata geçirilen, metabolik ve nadir bir hastalık grubu olan Lizozomal Depo Hastalıkları odağında çözüm geliştiren girişimcilere yönelik başlattığı Care4Rare projesinin Demoday etkinliği gerçekleştirildi.Care4Rare programı, Sanofi’nin Sağlık Bakanlığı Nadir Hastalıklar Sağlık Strateji Belgesi ve Eylem Planı’na uygun birçok dijital çözüm, yaklaşım, fikir ve paydaşlarla iş birliği fırsatları yaratmayı hedeflediği projesi. Lizozomal Depo Hastalıkları başta olmak üzere nadir hastalıklara sahip hastaların tanı, tedavi ve günlük yaşam süreçlerindeki öncelikli sorunlarına girişimci gözü ile bulunan çözümlerin hayata geçirilmesi için kapsamlı destekler sunuluyor.Care4Rare'in Demo Day'inde sunum yapan girişimler şu şekilde:Umaxlife: Biyomarkerlara entegre olarak veri toplayabilen, derin öğrenme ile akıl sağlığının insan bedenine etkisini ölçümleyen dijital terapötik platform.Inorare: Nadir hastalıklarla mücadele edenlerin en çok kullandığı medikal cihazlardan biri olan TAK kateterlerin ev ortamında kullanıcı tarafından en az 10 kez sterilize edilip tekrar kullanımını sağlayacak bir kişisel sterilizasyon sunuyor.Pons: Hastane dışında yapay zeka destekli mobil ultrason teknolojisi ile erken aşama yüksek riskli kanser vakalarının tespitini mümkün kılan teknolojiye sahip girişim.RareGlow: Hastalığın seyrine göre fizyoterapistin ailelere verdiği egzersiz programını 3 boyutlu bir modelle uygulamaya entegre ediyor.RareSum: Doktorların yüklediği anonim hasta profillerini inceleyen, bugüne kadar yayınlanmış vaka çalışmalarıyla eşleşme sağlayan, doktorun teşhis ve tedavisini bilimsel kanıtlarla desteklemesini sağlayan, yapay zeka tabanlı karar destek mekanizması

Hit Consultant
Dec 17th, 2024
Brightinsight, Sanofi To Build Drug Companion Apps For Its Major Specialty Therapies

What You Should Know:– BrightInsight, Inc., a provider of regulated digital health solutions, has announced an expanded multi-year partnership with Sanofi, a global biopharmaceutical company. This expanded partnership builds on a successful collaboration that began in 2022 when Sanofi selected the BrightInsight Platform to accelerate the development of a SaMD for one of its specialty care medicines.– The goal of the collaboration aims to accelerate Sanofi’s drug development timeline and improve patient outcomes through innovative digital health solutions.Accelerating Time-to-Market for New TherapiesSanofi aims to cut its drug development timeline in half, and this partnership with BrightInsight will play a key role in achieving that goal. By leveraging BrightInsight’s platform and technology, Sanofi can streamline the development and deployment of digital health solutions that support clinical trials, enhance patient engagement, and improve medication adherence.Enhancing Patient Experience with “MyWay”Under the expanded partnership, Sanofi will utilize BrightInsight’s “MyWay” mobile application, a Software as a Medical Device (SaMD) solution designed to empower patients in managing their health conditions. MyWay offers several key features:Symptom Tracking: Allows patients to track their symptoms, such as flares or disease progression.Allows patients to track their symptoms, such as flares or disease progression. Medication Management: Helps patients manage their medications, including tracking injections and adherence.Helps patients manage their medications, including tracking injections and adherence. Financial Tracking: Enables patients to track medical expenses in select countries.Enables patients to track medical expenses in select countries